UF startup and Sid Martin Biotech alum AxoGen, Inc reported that its Common Stock (NASDAQ:AXGN) shares hit a new 52-week high during mid-day trading on Tuesday. The company traded as high as $56.85 and last traded at $54.90, with a volume of 4762 shares changing hands. The stock had previously closed at $56.60. The company has a quick ratio of 2.81, a current ratio of 3.32 and a debt-to-equity ratio of 0.82. The firm has a market cap of $1.90 billion, a PE ratio of -182.10 and a beta of 0.04.
As a female chief executive officer in the healthcare industry CEO Karen Zaderej often stands out in a male-dominated industry. This month she stood out for another reason – as the Ernst & Young Entrepreneur of the Year 2018 Award winner for the state of Florida in the healthcare category.
Zaderej leads AxoGen, a UF startup and UF Innovate | Sid Martin Biotech graduate. She said she typically stands out as the lone woman in a group shot of her peers. Even among the other entrepreneur winners in additional categories, she remained the lone female for Florida. She noted that there is still a glass ceiling that “limits the opportunity” for women to be fully recognized and contribute as capable leaders. However, Zaderej noted some investors are “putting their money where their mouths are” in order to promote diversity at the C-suite level and on boards of directors.
Karen Zaderej, CEO of Alachua-based AxoGen Inc., a UF startup, took home the prize in the Health Care category. Her company focuses on the development and commercialization of technologies for peripheral nerve regeneration and repair.
“I am honored to be named an Entrepreneur Of The Year award winner in Florida,” Zaderej said in a statement. “AxoGen’s success is the result of a true team effort and a patient-focused culture… We have tremendous opportunity to improve quality of life and offer hope to patients with debilitating nerve damage.”
UF startup AxoGen, a global leader in developing and marketing innovative surgical solutions for peripheral nerves, announced that its Board of Directors has elected Karen Zaderej as Chairman of the Board in addition to her current role as President and Chief Executive Officer (CEO), effective immediately. Zaderej succeeds Jamie M. Grooms, who will remain a Director of the Board.
In her role as Chairman of the Board, Zaderej will lead efforts in developing and implementing the Company’s strategic vision. AxoGen is creating a platform for nerve repair with innovative solutions and expanding applications to improve the quality of life for patients with peripheral nerve damage.
UF startup AxoGen, Inc., a global leader in developing and marketing innovative surgical solutions for peripheral nerves, announced it has received a 2018 Employee Engagement Best Practices Award. The annual award, sponsored by DecisionWise International, recognizes top performing companies in the area of employee engagement and company culture. AxoGen is one of only five companies to receive the 2018 award.
“It is gratifying to be recognized as a best practice company for employee engagement and culture,” said Karen Zaderej, president and CEO of AxoGen. “We are passionate about creating solutions for patients with peripheral nerve damage or discontinuities and our AxoGenic values are central to our culture. Open, honest, and respectful communication along with individual ownership and empowerment are key characteristics of our culture that allow us to attract, develop and promote outstanding associates.”
UF startup AxoGen, Inc., a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, has selected Dylan Harvey to ride on the 2018 Donate Life Rose Parade® float that will be featured in the annual Tournament of Roses® parade. The parade takes place in Pasadena on New Year’s Day.
Dylan Harvey, 19, was a sophomore in high school when he was seriously injured in a motorcycle accident and spent several weeks in the ICU undergoing multiple surgeries to repair injuries to his left arm and right leg. Once stabilized, however, Dylan was unable to move most of his left arm due to significant nerve damage. Damaged peripheral nerves can be surgically repaired, but the window of time for effective outcomes is limited, so expertise from a nerve specialist must be sought quickly. Fortunately, the Harvey family found David Adelson, M.D., the director of Barrow Neurological Institute and chief of pediatric neurosurgery at Phoenix Children’s Hospital. Dr. Adelson performed surgery and utilized AxoGen’s Avance® Nerve Graft to help repair the damaged nerve in Dylan’s left arm.
UF startup AxoGen, Inc., a global leader in developing and marketing innovative surgical solutions for peripheral nerve damage, outlined its broadening platform for nerve repair at the company’s annual Analyst and Investor Day in New York City. The company highlighted surgical solutions for nerve damage in its core applications of extremity trauma, nerve compression, and oral and maxillofacial procedures. Additionally, the company announced its newest application in breast reconstruction neurotization and outlined its continued effort to evaluate expansions of the company’s portfolio of products in the surgical management of pain.
“AxoGen has evolved from an initial niche product company in a new market to one with a comprehensive platform for nerve repair in an emerging peripheral nerve market,” said Karen Zaderej, president and CEO of AxoGen. “We are pleased to partner with surgeons to develop advanced procedures for the repair of peripheral nerves across an increasing range of applications with an expanding portfolio of products.”
UF startup AxoGen, Inc., a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced the appointment of Jon S. Gingrich to the newly created role of Chief Commercial Officer. Gingrich brings more than 20 years of global medical device and health care sales, marketing, and general management experience to AxoGen. As a member of the AxoGen executive leadership team, Gingrich will report directly to Karen Zaderej, President and CEO, and will oversee the development and execution of the company’s sales and marketing strategies.
WCJB (TV20) featured UF startup AxoGen, Inc. on its Tech Tuesday segment. Alachua-based AxoGen, a company focused in the area of peripheral nerve repair, is a startup that licenses UF technology and has worked with both the Innovation Hub at UF and the Sid Martin Biotechnology Institute incubators.
Moving from an economy that relies heavily on tourism to one that has a large stake in biotech is a big leap. And it calls for a long-term, well developed strategy. That’s what Governor Jeb Bush was after back in 2003. He began by using federal stimulus dollars as bait, luring the Scripps Research Institute to Florida. He next urged the state legislature in 2006 to create an Innovation Investment Fund to attract world-class research and development. His efforts worked, eventually allowing state universities and their research partners to leverage public and private dollars to commercialization of emerging technologies.
All of this success has translated into financial gains for cities across the state, and Gainesville is one city that has seen its biotech economy grow by leaps and bounds.
“Greater Gainesville has evolved into a region fueled by research, business and a smart, young and creative workforce that both thrives on, and is a catalyst for innovation,” said Susan Davenport, CEO of Gainesville Chamber of Commerce.